NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice

CompletedN/A

Sponsor: AstraZeneca

Conditions: Heart Failure, Reduced Ejection Fraction

Interventions: Dapagliflozin

Countries: Italy

This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with dapagliflozin according to the approved HFrEF indication. The study is aimed at providing insights into real-world drug utilization and treatment patterns of dapagliflozin in the Italian HFrEF setting, as well as patient-reported outcomes including quality of life.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age equal or above 18 years old at the initiation of treatment with dapagliflozin
* Participant received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction (HFrEF) in accordance with the approved local dapagliflozin product label, i.e. with an ejection fraction of 40 percent or less
* Signed and dated informed cconsent obtained prior to enrollment into the study

Exclusion Criteria:

* Participant is enrolled less than 14 days or more than 45 days following the initiation of treatment with dapagliflozin
* Prior treatment with dapagliflozin or other treatment with a medicine of the same drug class (sodium-glucose co-transporter-2 - or SGLT2 - inhibitors)
* Initiation of dapagliflozin outside of the approved local dapagliflozin product label for HFrEF
* Diagnosis of Type 1 Diabetes

Locations (11)

Brescia, BS, Italy
Catanzaro, CZ, Italy
Foggia, FG, Italy
Florence, FI, Italy
Genova, GE, Italy
Monza, MB, Italy
Milan, MI, Italy
Roma, RM, Italy
Roma, RM, Italy
Trieste, TS, Italy
Naples, Italy